Novartis Reports Two Positive US Phase III Programs in COPD for QVA149, NVA237
May 20, 2015 at 11:32 AM EDT
Novartis announced today positive results from two pivotal Phase III clinical trial programs for QVA149 (indacaterol/glycopyrronium ...
